Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-…

Background The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March,
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …

Global dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G
are suggestive of a selective advantage but may also be due to a random founder effect. We …

Background The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in
England. We aimed to investigate whether increases in the proportion of infections with this …

COVID-19 vaccine design and vaccination rollout need to take into account a detailed
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and …

Background Surface-active antiseptics, such as chlorhexidine, are increasingly being used
as part of intervention programs to prevent methicillin-resistant Staphylococcus aureus (…

Background Lateral flow devices (LFDs) for rapid antigen testing are set to become a cornerstone
of SARS-CoV-2 mass community testing, although their reduced sensitivity compared …

The 3.1-Mb genome of an outbreak methicillin-resistant Staphylococcus aureus (MRSA) strain
(TW20) contains evidence of recently acquired DNA, including two large regions (635 kb …

Background Development of an effective vaccine against the pathogenic blood-stage infection
of human malaria has proved challenging, and no candidate vaccine has affected blood-…

There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement
to existing diagnostic capabilities and for determining community seroprevalence. We …